KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Common Equity (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Common Equity for 16 consecutive years, with $371.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 6.59% to $371.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $371.9 million, a 6.59% increase, with the full-year FY2025 number at $371.9 million, up 6.59% from a year prior.
  • Common Equity was $371.9 million for Q4 2025 at Biolife Solutions, up from $353.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $489.3 million in Q3 2021 to a low of $208.8 million in Q1 2021.
  • A 5-year average of $370.9 million and a median of $353.2 million in 2025 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 327.31% in 2021, then fell 24.78% in 2023.
  • Biolife Solutions' Common Equity stood at $478.0 million in 2021, then fell by 23.82% to $364.2 million in 2022, then fell by 7.28% to $337.7 million in 2023, then rose by 3.33% to $348.9 million in 2024, then grew by 6.59% to $371.9 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Common Equity are $371.9 million (Q4 2025), $353.7 million (Q3 2025), and $347.2 million (Q2 2025).